Jessemae Welsh, MD
Surgical Oncology · Spokane, WANPI 1194950295
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $796 of the $912 with a category attached, or 87.2%. 8 manufacturers reported payments, led by Myriad Genetic Laboratories, Inc. at 26.7% of the total. Reporting peaked in 2024 at $358 and has fallen 77.6% since, to $80 in 2025. That places this record below the midpoint for surgical oncology clinicians in WA, where the typical reported total is $5,112.
Across 20 payments — averaging $45.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$244
- Stryker$221
- Merit Medical Systems Inc$199
- KUB Technologies Inc.$116
- Seagen Inc.$75
- Medtronic$25
- plus $34 from 2 others
What the payments were for
- Consulting fees$253%
- Food & beverage$79687%
- Education$758%
- Entertainment$162%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 8 | $244 |
| Stryker | 3 | $221 |
| Merit Medical Systems Inc | 3 | $199 |
| KUB Technologies Inc. | 2 | $116 |
| Seagen Inc. | 1 | $75 |
| Medtronic | 1 | $25 |
| AstraZeneca | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
How this compares
$912 in reported general payments places this provider in the 25th percentile of 31 surgical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 74 | $454 |
| Cefadroxil | 18 | $238 |
| Ondansetron OdtOndansetron | 34 | $236 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 26 | $231 |
| Gabapentin | 32 | $214 |
| Naproxen | 44 | $173 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Spokane
- Jennifer PaskoSpokane$6K
- Michalina KupsikSpokane$5K
- Maryam ParvizSpokane$3K
- Rebecca KirschnerSpokane$2K
- Ryan HolbrookSpokane$88
- Deborah MartinezSpokane$38
- Cary KaufmanBellingham$171K
- Flavio RochaSeattle$27K
- Evan OngSeattle$18K
- Benjamin AndersonSeattle$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.